glp-1 risks and side effects Adverse of Receptor Agonists Ozempic and GLP-1 Drugs: Risk
Description
References Beaudry, J
What Are The Qualifications For Oral Semaglutide
, 2017, 60.9: 562-564
This study was an observational cohort investigation using electronic health record data from the United States Department of Veterans Affairs and included 606,434 patients with type 2 diabetes who newly started either a GLP-1 medication or, as a comparator, a sodium-glucose cotransporter-2 inhibitor (a type 2 diabetes medication that doesnt affect appetite and reward pathways) based on filled outpatient pharmacy records
Geremia A, Jewell DP
